Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli

Towards Patient Centricity: LEO Pharma

Industry plays a pivotal role in making sure patient needs are not overlooked by the wider healthcare community.

UCB’s bimekizumab tops J&J’s Stelara in psoriasis study

Amgen stumps up $13.4bn to claim Otezla from Celgene

Novartis ups 2019 guidance after strong Q2

Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis drug Cosentyx being the star performer.

BMS will shed Otezla to push Celgene takeover through

Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion takeover of Celgene through the financial regulatory seas.